Flow cytometry analysis, performed on the same cohorts of HD and melanoma patients, did not reveal any decrease in the percentage of circulating CD160-GPI positive NK cells neither between the two groups nor for the 6 melanoma patients exhibiting high levels of sCD160 (data not shown), suggesting that the presence of sCD160 in the blood flow did not result from membrane-bound CD160-GPI proteolytic cleavage. This evidence concerns the gene CD160 and melanoma.